IVUS-guided group (pϭ0.029), resulting in significant difference in ST-elevation MI between two groups (9.8% vs. 2.4%, pϭ0.030). Conclusions: IVUS-guided two-stent techniques was associated with significantly reduced late stent thrombosis, with resultant reduction of ST-elevation myocardial infarction.
The SPIRIT II, III and IV randomized controlled trials (RCT) compared the second-generation everolimus-eluting stent (EES) to the first-generation paclitaxel-eluting stent (PES). Summary-level data of each study was pooled using meta-analytic techniques. We evaluated the impact of gender on adverse events stratified by DES type. Relative risks and 95% confidence intervals were calculated for the following outcomes: definite or probable stent thrombosis (ST), target lesion revascularization (TLR), myocardial infarction (MI), major adverse cardiovascular events (MACE) and cardiac death. Results: Women (nϭ1583, 31.7%), were older, more often diabetic and less likely to have multivessel disease compared to men. After a weighted mean follow-up of 2.3 years, among patients receiving PES, the incidence of MACE was significantly higher while rates of MI and TLR were modestly higher among women (Figure) . In contrast, MACE rates were lower with EES than PES in both men and women, and outcomes were similar in men and women receiving EES. Rates of ST (0.5% vs. 0.7%, pϭ0.65) and cardiac death (0.9% vs. 1.0%, pϭ0.95) in EES-treated patients did not differ in women vs. men.
Conclusions:
In this pooled analysis of RCT, adverse events were modestly higher among women compared to men treated with PES. In contrast, outcomes were improved with EES in both men and women such that female sex was no longer associated greater MACE. 
